Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 13.64% and 8.63%, respectively, for the quarter ended June 2024. Do the numbers...

Adenoid Cystic Carcinoma Market According to DelveInsight, the dynamics of the Adenoid Cystic Carcinoma market are expected to evolve in the coming...

Eli Lilly, Pfizer, AbbVie and Biogen are part of the Zacks top Analyst Blog.

Walmart, Cardinal Health and Eli Lilly have been highlighted in this Investment Ideas article.

Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.

The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare...

Lilly (LLY) delivered earnings and revenue surprises of 48.48% and 14.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to...

Eli Lilly on Thursday reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion...